Publications
Building Commercial Certainty at 2,000L
PharmaTech Outlook, June 2026
As industry capacity grows, the real differentiator isn’t scale.
It’s execution discipline under regulatory scrutiny.
In PharmaTech Outlook latest feature article, Marc Goemans, our Chief Commercial Officer, outlines how:
- Structured scale-up protects PPQ timelines
- FDA-approved U.S. infrastructure strengthens launch economics
- Inspection readiness must be operational — not event-driven
- 175+ years of collective cGMP experience shapes daily execution
Commercial biologics manufacturing is not defined by equipment alone.
It’s defined by how consistently teams perform at scale.
Now Operational: 2000L Single-Use Commercial Capacity in the U.S.
Bora Biologics’ expanded 2000L single-use capabilities support late-stage development and commercial GMP manufacturing in our San Diego FDA registered facility.
